• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Stilley William B. Iii

    3/8/23 4:45:24 PM ET
    $AVCO
    Building operators
    Real Estate
    Get the next $AVCO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Stilley William B. III

    (Last) (First) (Middle)
    C/O AVALON GLOBOCARE CORP.
    4400 ROUTE 9 SUITE 3100

    (Street)
    FREEHOLD NJ 07728

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Avalon GloboCare Corp. [ ALBT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/01/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $5.2 01/01/2023 A 8,000 (1) 12/31/2027 Common Stock, $.0001 par value 8,000 $0 8,000 D
    Stock Option (right to buy) $8.2 01/01/2022 A 8,000 (1) 12/31/2026 Common Stock, $.0001 par value 8,000 $0 8,000 D
    Stock Option (right to buy) $11.2 01/01/2021 A 8,000 (1) 12/31/2025 Common Stock, $.0001 par value 8,000 $0 8,000 D
    Explanation of Responses:
    1. The stock options vest over one year in equal quarterly installments.
    /s/ William B. Stilley III 03/08/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVCO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AVCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalon GloboCare Announces NASDAQ Ticker Symbol Change from "AVCO" to "ALBT"

      Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 Symbol Change Better Reflects Avalon's New Focus on Laboratory Services and Biotherapeutics FREEHOLD, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company") (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced that its ticker symbol will change on the NASDAQ Stock Exchange from "AVCO" to "ALBT" at the open of market trading on Thursday, November 10, 2022. David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon, commented, "Yesterday we announced a transformative acquisition of Laboratory Services MSO, LLC,

      11/9/22 4:00:00 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Signs Definitive Agreement for Transformational Acquisition of Leading Laboratory with 2021 Unaudited Revenue in Excess of $25 Million

      Company to acquire a majority interest in Laboratory Services MSO, LLC, a leading reference laboratory with 2021 unaudited revenue in excess of $25 million, net income in excess of $10 million and over 600,000 tests completed since inception Cash portion to be financed with a private placement of $15 million of Avalon preferred stock, convertible at a floor of $1.00 per share, with leak-out provisions, no warrants and a 9-month lock up Company to Begin Trading under New Symbol "ALBT" on November 10, 2022 FREEHOLD, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. ("Avalon" or the "Company")(NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and

      11/8/22 9:10:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon Globocare to Present at the LD Micro Main Event XV on October 26th

      Freehold, New Jersey--(Newsfile Corp. - October 19, 2022) - Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer of Avalon GloboCare, will be presenting at the 15th annual LD Micro Main Event being held on October 25 - 27, 2022 at the Luxe Sunset Boulevard Hotel in Los Angeles, California.Presentation details:Event:LD Micro Main Event XVDate:Wednesday, October 26th, 2022Time:4:00 PM PT/ 7:00 PM ET Register to watch the virtual presentation here.Management will be available for one-on-one meetings

      10/19/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    SEC Filings

    See more
    • Avalon GloboCare Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/22/23 4:49:04 PM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 10-Q filed by Avalon GloboCare Corp.

      10-Q - Avalon GloboCare Corp. (0001630212) (Filer)

      11/14/23 4:30:53 PM ET
      $AVCO
      Building operators
      Real Estate
    • Avalon GloboCare Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Avalon GloboCare Corp. (0001630212) (Filer)

      11/9/23 4:30:46 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Avalon GloboCare Corp. (Amendment)

      SC 13D/A - Avalon GloboCare Corp. (0001630212) (Subject)

      1/24/24 8:35:42 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Tauzin W J

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:12:55 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Sanders Steven Andrew

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/9/23 11:11:22 AM ET
      $AVCO
      Building operators
      Real Estate
    • SEC Form 4 filed by Stilley William B. Iii

      4 - Avalon GloboCare Corp. (0001630212) (Issuer)

      3/8/23 4:45:24 PM ET
      $AVCO
      Building operators
      Real Estate

    $AVCO
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

      Goal of Partnership is to expand Avalon's R&D pipeline to include innovative companion diagnostics in association with the company's ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon's companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ:AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has signed a memorandum of understanding (MOU) with Lu Daopei Hematol

      5/18/22 9:00:00 AM ET
      $AVCO
      Building operators
      Real Estate
    • Siyata Mobile Appoints Peter Goldstein as Chairman and Adds Seasoned Public Company Executive Luisa Ingargiola to Board of Directors

      VANCOUVER, British Columbia, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Siyata Mobile Inc. (Nasdaq: SYTA, SYTAW) (“Siyata” or the “Company”), a leading global developer and provider of cellular communications solutions for enterprise customers, today announces the appointment of Peter Goldstein, currently a Siyata Board member, as the Chairman of its Board of Directors. In addition, Luisa Ingargiola, who has extensive experience on public company boards and in the capital markets, has been appointed to the Board of Directors effective as of the shareholders meeting on February 23, 2021. “Peter’s many years in working with emerging growth, publicly traded companies is paramount to our asking him to

      2/9/21 10:30:49 AM ET
      $SYTA
      $AVCO
      $SOLO
      $UAVS
      Telecommunications Equipment
      Telecommunications
      Building operators
      Real Estate